Current Hepatitis Reports

, Volume 3, Issue 1, pp 38–43

Mechanisms of drug resistance to current and future antiviral therapies for hepatitis C virus infection

  • Jean-Michel Pawlotsky
Article

DOI: 10.1007/s11901-004-0007-8

Cite this article as:
Pawlotsky, J. Curr hepatitis rep (2004) 3: 38. doi:10.1007/s11901-004-0007-8

Abstract

The treatment of chronic hepatitis C is currently based on the pegylated interferon alpha and ribavirin combination. Despite this treatment, a significant number of patients still fail to eradicate the virus. The mechanisms underlying this failure are unknown, but indirect evidence suggests that chronic infection is associated with phenomena that protect hepatitis C virus (HCV) from the antiviral action of interferon alpha and hinder the clearance of infected cells. Viral factors responsible for true "HCV resistance" probably play a partial role. Numerous new HCV drugs are currently at the developmental stage. It is foreseeable that specific HCV inhibitors will select resistant viral variants. As a result, combination therapy will probably become the standard of care in chronic hepatitis C.

Copyright information

© Current Science Inc. 2004

Authors and Affiliations

  • Jean-Michel Pawlotsky
    • 1
  1. 1.Service de VirologieHôpital Henri MondorCréteilFrance